Home Protein Tyrosine Kinase Axl

Axl Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S0071 RU-301 RU-301 is a pan-TAM receptor (Axl, Tyro3 and Mertk) inhibitor that blocks the Axl receptor dimerization site with Kd of 12 μM and IC50 of 10 μM, respectively.
E1818 PF-07265807 PF-07265807(TAM&Met-IN-1) is a dual inhibitor of AXL and MER, which exhibits anti-tumor effects. It also enhances the function of dendritic cells to cross-prime CD8+ T cells.
S4001 Cabozantinib S-malate Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.
Sci Rep, 2025, 15(1):35889
Scientific Reports, 2025, 35889
bioRxiv, 2025, 2025.08.15.670608
Verified customer review of Cabozantinib S-malate
S1561 BMS-777607 BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
Cell Rep, 2025, 44(8):116096
Front Immunol, 2025, 16:1601420
Endocrinology, 2025, 166(11)bqaf146
Verified customer review of BMS-777607
S7014 Merestinib (LY2801653) Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. This compound also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.
Mol Oncol, 2025, 19(8):2366-2387
Molecular Oncology, 2025, 2366-2387
NPJ Breast Cancer, 2024, 10(1):65
S8573 Sitravatinib (MGCD516) Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
Translational Cancer Research, October 2019, 2425-2438
Cancer Research, October 15, 2025, 3983-3998
Neuro-Oncology, May 2025, 1372–1384
S7669 NPS-1034 NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
Neuro-Oncology, May 2025, 1372-1384
Molecular Cancer Therapeutics, February 01 2024, 212-222
Nat Commun, 2023, 14(1):4162
S7325 UNC2881 UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.
Frontiers in Bioengineering and Biotechnology, 2022, 788987
Cell Rep, 2020, 30(11):3671-3681
Cell Reports, 2020, 3671-3681
S8404 S49076 S49076 is a novel, potent inhibitor of Met (c-Met), AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.
Mol Brain, 2020, 4;13(1):66
S6870 Ningetinib Ningetinib (CT-053, DE-120, CT053PTSA) is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. This compound exhibits antitumor activity.
E6733New Adrixetinib TFA Adrixetinib TFA(Q702 TFA) is an orally active, selective triple kinase inhibitor of CSF1R, Mer, and Axl receptors within the TAM (Tyro3/Axl/Mer), exhibiting Kd of 8.7 nM (CSF1R), 0.8 nM (Mer), and 0.3 nM (Axl). It also binds the ATP-binding pockets of these RTKs to block ligand-induced autophosphorylation, disrupting downstream PI3K/Akt and Gas6-mediated survival signaling while repolarizing tumor-associated macrophages from pro-tumorigenic M2 to anti-tumor M1 phenotypes.
E0142 XL092

XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.